This is exactly what I see as the the motivation for his disclosure. He needs to create the impression of options for the company.
Currently he has no real options, including another round of equity sales, so he has no leverage in negotiations.
The smart thing to do would be to agree to a deal on any molecule that will give him a decent up-front. The additional cash will give him the ability to negotiate a much richer deal on the other indications.
News 
Market Data 
Discover 
AI
